Imaneh Roshanzamir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Imaneh Roshanzamir has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hassan Mehrad-Majd
Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Mehdi Bakhshaee
Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Abolfazl Zanghaei
Department of Biomedical Engineering and Biophysics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication Ehsan Khadivi
Sinus and Surgical Endoscopic Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication- Ermia Mousavi Mohammadi
Department of Otolaryngology ‐ Head & Neck Surgery Mashhad University of Medical Sciences Mashhad Iran
1 shared publication - Fatemeh Bavi
Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences
1 shared publication
Latest Publications
- 3 November 2026
- Published by Wiley in The Laryngoscope
Effect of Topical Tranexamic Acid in Acute Spontaneous Epistaxis: A Randomized Controlled Trial
Objective: Persistent epistaxis and early rebleeding remain clinical challenges despite the self‐limiting nature of many cases. Identification of a simple, noninvasive strategy for hemostasis and recurrence prevention remains a clinical priority. Topical tranexamic acid (TXA) is a potential hemostatic agent, but evidence regarding its effectiveness, particularly for rebleeding, is limited and inconsistent. This study evaluated the role of topical TXA in controlling bleeding and preventing rebleeding in acute spontaneous epistaxis. Methods: In this randomized, double‐blind, placebo‐controlled trial, patients presenting with acute spontaneous epistaxis unresponsive to initial first‐aid measures were enrolled and randomly assigned to receive topical tranexamic acid (TXA) or placebo. Results: A total of 162 patients were included in the study, including 76 in the TXA group and 86 in the control group. Topical TXA was significantly more effective than placebo in achieving initial hemostasis in the emergency department setting ( p = 0.047). No significant differences were observed in rebleeding within 24 h (risk ratio 0.45 (95% CI, 0.17–1.24; p = 0.119)), or in significant rebleeding within 24 h (risk ratio: 1.50 (95% CI, 0.26–8.70; p = 0.651)). Conclusion: In spontaneous epistaxis, the direct application of topical tranexamic acid to the bleeding site is a useful adjunct for achieving hemostasis. This targeted approach may allow effective bleeding control with a smaller amount of the drug, potentially reducing the risk of adverse effects associated with higher doses. Level of Evidence: 1
- 3 November 2026
- Published by Wiley in The Laryngoscope
Effect of Topical Tranexamic Acid in Acute Spontaneous Epistaxis: A Randomized Controlled Trial
Objective: Persistent epistaxis and early rebleeding remain clinical challenges despite the self‐limiting nature of many cases. Identification of a simple, noninvasive strategy for hemostasis and recurrence prevention remains a clinical priority. Topical tranexamic acid (TXA) is a potential hemostatic agent, but evidence regarding its effectiveness, particularly for rebleeding, is limited and inconsistent. This study evaluated the role of topical TXA in controlling bleeding and preventing rebleeding in acute spontaneous epistaxis. Methods: In this randomized, double‐blind, placebo‐controlled trial, patients presenting with acute spontaneous epistaxis unresponsive to initial first‐aid measures were enrolled and randomly assigned to receive topical tranexamic acid (TXA) or placebo. Results: A total of 162 patients were included in the study, including 76 in the TXA group and 86 in the control group. Topical TXA was significantly more effective than placebo in achieving initial hemostasis in the emergency department setting ( p = 0.047). No significant differences were observed in rebleeding within 24 h (risk ratio 0.45 (95% CI, 0.17–1.24; p = 0.119)), or in significant rebleeding within 24 h (risk ratio: 1.50 (95% CI, 0.26–8.70; p = 0.651)). Conclusion: In spontaneous epistaxis, the direct application of topical tranexamic acid to the bleeding site is a useful adjunct for achieving hemostasis. This targeted approach may allow effective bleeding control with a smaller amount of the drug, potentially reducing the risk of adverse effects associated with higher doses. Level of Evidence: 1
- 14 February 2025
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 145 (4) , 313-318
The auxiliary effect of vitamin D in the treatment of chronic rhinosinusitis with nasal polyposis, a clinical trial
Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) is a prevalent chronic inflammatory disorder of the nasal cavity and paranasal sinus with benign polypoid masses. Recent evidence highlights the immunomodulatory role of Vitamin D (Vit D) in mitigating inflammation associated with CRSwNP. The aim of this study is to examine the effect of Vit D on the improvement of CRSwNP. This randomized, double-blind clinical trial was conducted on 59 patients with CRSwNP. All patients with Vit D deficiency (25OH Vit D level < 20 ng/mL) or insufficiency (p = 0.02, p = 0.03 respectively). The administration of Vit D after ESS is relatively effective in the improvement of CRSwNP symptoms. This finding highlights the possibility of developing an efficient, safe, and cost-effective therapy for patients with CRSwNP.
- 14 February 2025
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 145 (4) , 313-318
The auxiliary effect of vitamin D in the treatment of chronic rhinosinusitis with nasal polyposis, a clinical trial
Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) is a prevalent chronic inflammatory disorder of the nasal cavity and paranasal sinus with benign polypoid masses. Recent evidence highlights the immunomodulatory role of Vitamin D (Vit D) in mitigating inflammation associated with CRSwNP. The aim of this study is to examine the effect of Vit D on the improvement of CRSwNP. This randomized, double-blind clinical trial was conducted on 59 patients with CRSwNP. All patients with Vit D deficiency (25OH Vit D level < 20 ng/mL) or insufficiency (p = 0.02, p = 0.03 respectively). The administration of Vit D after ESS is relatively effective in the improvement of CRSwNP symptoms. This finding highlights the possibility of developing an efficient, safe, and cost-effective therapy for patients with CRSwNP.
- Open Access
- 7 September 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 7 (5) , 1343-1350
Mucormycosis in pre‐COVID‐19 and COVID‐19 era: A study of prevalence, risk factors and clinical features
Objective: Mucormycosis is a rare yet devastating fungal disease with a frequently fatal outcome. The purpose of this study was to compare the prevalence of mucormycosis, evaluate its risk factors, and assess the patients' outcomes in pre‐COVID‐19 and COVID‐19 era.Methods: In this retrospective observational study, clinical data of 158 patients with confirmed histopathological diagnosis of mucormycosis were collected from the medical records departments of Imam Reza and Ghaem hospitals, Mashhad, Iran during 2018–2021. The collected data were risk factors associated with mucormycosis including age, gender, underlying diseases, details of corticosteroid administration, and complications such as blindness and mortality.Results: Of 158 studied patients, 48 patients were diagnosed in the pre‐pandemic period whereas 110 cases were admitted during the pandemic era. COVID‐19 associated mucormycosis (CAM) was observed in 58.1% of the pandemic cases. In the pre‐pandemic period, cancer (89.5% vs. 39%, p < .001) was significantly more prevalent while during the pandemic era, the prevalence of diabetes mellitus (16.7% vs. 51%, p < .001) was remarkably higher. Moreover, the mortality rate of mucormycosis was considerably reduced after the pandemic (64.6%–45.4%), especially in CAM patients (35.9%).Conclusion: The COVID‐19 pandemic has led to an increased prevalence of mucormycosis, due to the convergence of interlinked risk factors such as diabetes mellitus, corticosteroid therapy, and COVID‐19. Therefore, clinicians must be aware of the probable occurrence of mucormycosis in the first or second week of COVID‐19 infection in vulnerable patients and use the steroids cautiously.Level of evidence: 4 Laryngoscope Investigative Otolaryngology, 2022.
- 7 September 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 7 (5) , 1343-1350
Open AccessMucormycosis in pre‐COVID‐19 and COVID‐19 era: A study of prevalence, risk factors and clinical features
Objective: Mucormycosis is a rare yet devastating fungal disease with a frequently fatal outcome. The purpose of this study was to compare the prevalence of mucormycosis, evaluate its risk factors, and assess the patients' outcomes in pre‐COVID‐19 and COVID‐19 era.Methods: In this retrospective observational study, clinical data of 158 patients with confirmed histopathological diagnosis of mucormycosis were collected from the medical records departments of Imam Reza and Ghaem hospitals, Mashhad, Iran during 2018–2021. The collected data were risk factors associated with mucormycosis including age, gender, underlying diseases, details of corticosteroid administration, and complications such as blindness and mortality.Results: Of 158 studied patients, 48 patients were diagnosed in the pre‐pandemic period whereas 110 cases were admitted during the pandemic era. COVID‐19 associated mucormycosis (CAM) was observed in 58.1% of the pandemic cases. In the pre‐pandemic period, cancer (89.5% vs. 39%, p < .001) was significantly more prevalent while during the pandemic era, the prevalence of diabetes mellitus (16.7% vs. 51%, p < .001) was remarkably higher. Moreover, the mortality rate of mucormycosis was considerably reduced after the pandemic (64.6%–45.4%), especially in CAM patients (35.9%).Conclusion: The COVID‐19 pandemic has led to an increased prevalence of mucormycosis, due to the convergence of interlinked risk factors such as diabetes mellitus, corticosteroid therapy, and COVID‐19. Therefore, clinicians must be aware of the probable occurrence of mucormycosis in the first or second week of COVID‐19 infection in vulnerable patients and use the steroids cautiously.Level of evidence: 4 Laryngoscope Investigative Otolaryngology, 2022.